Industry News Archive

FDA Approves Ibrutinib for Pediatric Patients with Chronic Graft Versus Host Disease

On August 24, 2022, the U.S  Food and Drug Administration (FDA) approved ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy. 

For more information, read the FDA announcement

Posted 8/25/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us